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APOLIPOPROTEIN E ALTERS THE ASSOCIATION OF 
 NEUROINFLAMMATION WITH ALZHEIMER’S DISEASE 
JACOB SANDS FRIEDBERG 
ABSTRACT 
 Alzheimer’s disease (AD) is a chronic neurodegenerative disease with a multitude 
of contributing genetic factors. The apolipoprotein E (APOE) allele e4 imparts a dramatic 
increase in the risk of developing Alzheimer’s disease, but the exact mechanism of this 
relationship is unknown. The e4 allele is associated with increased Ab plaques, 
neurofibrillary tangles, and a heightened inflammation state, all pathological hallmarks of 
Alzheimer’s disease. To test the hypothesis that microglia and related cytokines were 
differentially associated with Alzheimer’s disease pathology based on the presence of e4, 
we compared individuals with and without the APOE e4 allele within a community based 
aging cohort (n = 186). Cellular density of Iba1, a marker of microglia, was positively 
associated with tau pathology as measured by AT8 immunostaining (b = 0.459, p = 
0.028) in e4 positive participants but not in e4 negative participants. Analysis of 
cytokines implicated in AD, i.e. IL-10, IL-13, IL-4, IL-1a, revealed a significant negative 
association with AT8 in e4 negative participants. The association of the anti-
inflammatory cytokines IL-10, IL-13, and IL-4 on tau pathology appeared to be mediated 
by ApoE protein levels, suggesting that these cytokines and the ApoE protein may 
interact to prevent increased tau pathology within e4 negative individuals. The pro-
inflammatory cytokine, IL-1a, was negatively associated with AT8 (b = -0.241,               
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p = 0.009) independent of Ab1-42 in e4 negative participants but not in e4 positive 
participants, suggesting a potential novel protective association. Overall, in e4 negative 
participants, elevated levels of IL-10, IL-13, IL-4, IL-1a are associated with less tau 
pathology. These associations are largely absent in the presence of e4 where tau 
pathology is significantly associated with microglial cell density. Taken together, these 
results suggest that APOE e4 mediates an altered inflammatory response and increased 
tau pathology independent of Ab pathology. 
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INTRODUCTION 
Alzheimer’s disease (AD), the leading cause of dementia, is a devastating 
neurodegenerative disorder. As of 2017, there are an estimated 5.5 million people in the 
United States (US) living with AD, and over 24 million worldwide (Ferri et al., 2005; 
Hebert, Weuve, Scherr, & Evans, 2013). One in ten Americans over the age of 65 has AD 
(Hebert et al., 2013). In the US over 96% of those living with AD are over the age of 65 
and that number is predicted to rise dramatically in the coming decades if there are no 
advancements in treatment (Hebert et al., 2013). The National Center for Health Statistics 
of Centers for Disease Control and Prevention (CDC) listed AD as the sixth leading cause 
of death in the US in 2015, resulting in 110,561 deaths (Murphy, Xu, Kochanek, Curtin, 
& Arias, 2017). However, this number may be higher in actuality and some estimates 
place AD as third leading cause of death in the US behind only heart disease and cancer 
because of the difficulty diagnosing AD and the large amount of comorbid complications, 
such as pneumonia and cardiovascular disease, that are associated with AD (Ives, 
Samuel, Psaty, & Kuller, 2009; James et al., 2014; Weuve, Hebert, Scherr, & Evans, 
2014). AD is a potent issue in the US where the aging of the baby boomer generation and 
improvements in medical care are poised to create an increasing large elderly population. 
Estimates project that by 2050 there will be 13.8 million people in the US with AD 
(Hebert et al., 2013).  
AD presents with a myriad of worsening symptoms that vary between individuals. 
The disease typically begins with mild cognitive impairment and minor memory loss. As 
the disease progresses it leads to worsening memory loss, decreased executive function, 
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mood and behavior changes, and failure to complete the activities of daily life. This can 
result in individuals becoming completely dependent on others for all of their basic 
needs. Underlying these symptoms are pathologic changes occurring in the brain over a 
span of several decades, resulting in widespread brain atrophy. The accumulation of the 
beta amyloid protein (Ab) into extracellular plaques and abnormally phosphorylated tau 
protein leading to intracellular neurofibrillary tangles (NFTs) are major pathological 
changes in AD. Their accumulation begins prior to the manifestation of clinical 
symptoms and follows a relatively conserved pattern of deposition within the brain (Thal, 
Rüb, Orantes, & Braak, 2002; Braak, Thal, Ghebremedhin, & Del Tredici, 2011) . While 
the extent of Ab deposition varies greatly among individuals the sequence of brain 
regions involved follows a predictable set of stages, beginning in the cortex and 
proceeding to deeper structures spreading lastly to the brainstem and cerebellum (Thal et 
al., 2000; Thal et al., 2002). Phosphorylated tau deposition follows a different 
progression, beginning in the brainstem and proceeding to the cortex (Braak et al., 2011).   
The Ab cascade hypothesis has been the dominant theory explaining the 
progression of pathology in AD. The Ab cascade hypothesis posits that Ab deposition is 
the primary insult driving subsequent pathology and neurodegeneration (Hardy & 
Higgins, 1992). The cascade is proposed to begin with an abnormal accumulation Ab that 
forms toxic plaques causing neuronal dysfunction and subsequent hyperphosphoryation 
of tau, a cytoskeletal protein, leading to intracellular neurofibrillary tangles (NFT), 
further cell damage and the death of neurons; this neuronal death reduces the number of 
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synapses and culminates in the clinical symptoms of AD. Much of the initial support for 
the amyloid cascade arose from the discovery of genetic mutations leading to abnormal 
Ab productions. The hypothesis was further supported by determining that neuritic 
plaques are composed of mostly Ab (Masters et al., 1985). In vitro studies found that Ab 
accumulated into plaques and cause associated neurotoxicity (Hoshi et al., 2003; 
Deshpande, Mina, Glabe, & Busciglio, 2006). Studies using transgenic mice expressing 
human amyloid precursor protein (APP) found that increased APP lead to higher Ab 
accumulation and cell damage (Games et al., 1995). Additionally, transgenic mice 
expressing APP exhibit behavioral and structural changes analogous to AD, however 
mature NFTs as seen in humans do not develop in these mouse models (Gschwind & 
Huber, 2002; Giasson, Lee, & Trojanowski, 2003; Schwab, Hosokawa, & McGeer, 2004; 
Ashe, 2005). Mouse studies were also used to examine the connection between amyloid 
and tau. Direct injection of Ab into transgenic mice expressing both APP and tau was 
shown to increase tau phosphorylation and lead to NFTs similar to those seen in AD 
(Gotz, Chen, van Dorpe, & Nitsch, 2001; Lewis et al., 2001; Oddo et al., 2003). The 
results of these studies and others led to the amyloid cascade hypothesis becoming the 
preeminent theory explaining the disease process of AD.  
Ab plaques are composed of varying components, largely consisting of the two 
pathological Ab isoforms, Ab1-40 and Ab1-42 (Masters et al., 1985). The more 
hydrophobic and cytotoxic Ab1-42 tends to more readily oligomerize and aggregate in 
plaques than Ab1-40, which diffuses easier through the stroma (Prelli, Castano, Glenner, & 
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Frangione, 1988; Burdick et al., 1992; Jarrett, Berger, & Lansbury, 2002; Walsh & 
Selkoe, 2007). Ab is a cleavage product of APP, a membrane bound glycoprotein with an 
unclear function (Kang et al., 1987). APP can be cleaved initially by either b-secretase or 
a-secretase respectively leading to amyloidogenic or non-amyloidogenic products 
following subsequent g-secretase cleavage (Ling, Morgan, & Kalsheker, 2003). These Ab 
peptides can then associate into oligomers and subsequently fibrils that accumulate in 
plaques (Castaño et al., 1986; Kirschner et al., 1987). It is important to note that Ab is 
observed under non-pathological conditions and is associated with increased 
neurogenesis, neuron survival, and long-term potentiation, however these interactions are 
not well understood (Clarris, Key, Beyreuther, Masters, & Small, 1995; Ishida, 
Furukawa, Keller, & Mattson, 1997; Dawkins & Small, 2014). Increasing the ratio of 
Ab1-42 to Ab1-40 may lead to more pathologic Ab deposition and the pathological 
conditions observed in AD (Haass et al., 1992; X. D. Cai, Golde, & Younkin, 1993; Ida 
et al., 1996).  
 
Genetic Support for Amyloid Cascade Hypothesis   
Much of the support for the involvement of amyloid in AD originated in the study 
of genetic mutations observed in familial Alzheimer’s disease (FAD). In FAD, autosomal 
dominant mutations occurring in the APP, PSEN-1, and PSEN-2 genes lead to abnormal 
Ab production and subsequent pathology (Bertram, Lill, & Tanzi, 2010). The role of the 
APP gene in AD pathology is further supported by the high incidence of early onset 
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familial Alzheimer’s disease observed in persons with Down’s syndrome (Masters et al., 
1985). The APP gene is located on chromosome 21 and the additional copy of the gene in 
Down’s syndrome is associated with an early development of AD-like pathology. 
Mutations in APP can result in increased activity of b-secretase, g-secretase, or alter the 
structure or processing of Ab, all ultimately leading to higher levels of pathologic Ab 
(Barage & Sonawane, 2015). The PSEN-1 and PSEN-2 genes encode the proteins 
presenilin1 and presnilin2 that catalyze the action of g-secretase; mutations in these genes 
can disrupt the normal function of g-secretase leading to increased levels of Ab, and 
several mutations have been associated with increased production of Ab1-42 specifically 
(Ling et al., 2003; Bentahir et al., 2006; Shen & Kelleher, 2007).  
In addition to mutations in these genes, the APOE gene is associated with 
increased risk of AD in both late onset FAD and the much more common sporadic 
Alzheimer’s disease, hereinafter referred to as AD (Goedert & Spillantini, 2006). APOE 
encodes apolipoprotein E (ApoE) that is expressed throughout the body. ApoE binds 
lipids and aids in their metabolism; it is largely concentrated in the liver and brain, where 
it functions in very low density lipoproteins and serves as the primary apolipoprotein 
respectively (Puglielli, Tanzi, & Kovacs, 2003; Barage & Sonawane, 2015). ApoE is 
secreted from astrocyte and microglia cells in the central nervous system (CNS) and 
combines with lipids to form lipoproteins, it can also bind Ab in conjunction with lipids 
or independently (Barage & Sonawane, 2015). The three major alleles of APOE, e2, e3, 
and e4, encode three different forms of ApoE that vary at two locations, containing two, 
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one, and zero cytosine residues respectively (Weisgraber, Rall, & Mahley, 1981). The 
distribution of alleles across populations is largely conserved. The APOE e3 allele is most 
common, 77-78%, followed by the e4 allele, 4-15%, and lastly the e2 allele found in 2-
8.4% of individuals (Farrer, 1997; Mahley & Rall, 2000; McKay et al., 2011). ApoE e4 is 
the pathological isoform and is associated with a dramatic increase in the risk for 
developing AD and a younger age of symptom onset, while e2 is may be protective for 
both AD and cognitive decline in general (Corder et al., 1993; Verghese, Castellano, & 
Holtzman, 2011; Shinohara et al., 2016). While the exact mechanism of how ApoE leads 
to increased AD pathology is not clearly defined there are several hypotheses involving 
specific characteristics of ApoE4. The three forms of ApoE possess different properties 
and binding affinities, namely for Ab (Zhong & Weisgraber, 2009; Frieden & Garai, 
2012). ApoE4 has a higher affinity for Ab than ApoE3 in a lipid-free form, while ApoE3 
has a higher affinity for Ab than ApoE4 when complexed with lipids (Strittmatter et al., 
1993; LaDu et al., 1994; Liu, Liu, Kanekiyo, Xu, & Bu, 2013). This may account for the 
increased phagocytosis and degradation by microglia of Ab complexed with ApoE3 
compared to ApoE4 (Q. Jiang et al., 2008; Kim, Basak, & Holtzman, 2009). 
Additionally, ApoE4 itself may be degraded at a higher rate than ApoE3 resulting in a 
lower absolute ApoE level in e4 carriers (Riddell et al., 2008; Keene, Cudaback, Li, 
Montine, & Montine, 2011). Impaired phagocytosis and degradation of Ab in e4 carriers 
may lead to decreased clearance of Ab and drive the increased Ab plaque accumulation 
in e4 carriers and the greater deposition of ApoE4 in plaques compared to ApoE2 and 
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ApoE3 (Liu et al., 2013).   
 
Limitations of the Amyloid Cascade Hypothesis 
One of the largest critiques of the amyloid cascade hypothesis is lack of consistent 
correlations between Ab plaques and dementia (Armstrong, 2014). Many studies report 
opposing results as to the causative relationship between plaque density and the extent of 
dementia (Armstrong, 2014). Furthermore, some reports show no association between 
plaques and age (Hyman, Marzloff, & Arriagada, 1993; McKenzie, Gentleman, Roberts, 
Graham, & Royston, 1994). These results support the claim that Ab does not accumulate 
linearly over time, that it instead can reach a plateau after which the degree of amyloid 
burden does not continue to increase. In addition, cognitive impairment in APP 
transgenic mice has been reported prior to the detection of plaques indicating that the 
symptoms of AD may precede plaque formation (Chapman et al., 1999; Moechars et al., 
1999; Lennart Mucke, 2000). The amyloid cascade hypothesis is also weakened by the 
fact that not all individuals with Ab plaques present with dementia (Klunk et al., 2009; 
Villemagne et al., 2011). The absence of a significant relationship between plaques and 
dementia has brought about a new hypothesis that soluble Ab oligomers, not insoluble 
plaques, drive AD pathology (Walsh & Selkoe, 2007). Soluble Ab, including oligomers, 
may increase synaptic loss and cognitive decline indicating their potential role as the 
central insult in AD (Lue et al., 1999; McLean et al., 1999; J. Wang, Dickson, 
Trojanowski, & Lee, 1999; Shankar et al., 2008). There are substantial complications 
	  	  
 
8	  
studying Ab oligomers as they are very easily influenced by environmental conditions 
and experimental artifacts can significantly alter results  (Bitan, Fradinger, Spring, & 
Teplow, 2005; Teplow et al., 2006). While Ab oligomers present a potential tract for the 
amyloid cascade hypothesis the results of studies examining oligomers must be carefully 
interpreted.        
A second limitation of the amyloid cascade hypothesis it the lack of a clear 
mechanism of how Ab and tau interact leading to NFTs. This has raised doubts as to 
whether Ab causes abnormal phosphorylation of tau or whether they are concurrent 
pathologies that can act independently of each other. Ab and tau are observed in both 
spatial and temporal separation, and can develop in the absence of the other in specific 
pathologies (Hyman et al., 1993; Yamada, 2003; Braak et al., 2011). Postmortem analysis 
of AD patients have revealed that the progression of Ab plaques and NFTs proceed in 
opposite directions, with Ab plaques beginning in the cortex and spreading to more basal 
structures while NFTs present in the reverse pattern (Thal et al., 2002; Braak et al., 2011). 
Additionally, phosphorylated tau, assessed via immunohistochemical staining, has been 
observed prior to the detection of Ab plaques, even decades earlier (Braak et al., 2011). 
These results weaken the claim that NFTs are a result of Ab plaques but does not 
eliminate the possibility that the two are related and may be involved as separate insults 
when occurring in the same location and may lead to worse pathology.    
 A third limitation of the amyloid cascade hypothesis is the validity of the 
commonly used transgenic mouse studies. Mice do not naturally become demented, and 
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artificially inducing AD-like pathology has a variety of issues, the most prevalent being 
the fact that APP transgenic mice do not develop NFTs or clear neurodegeneration, even 
though they may exhibit some memory deficits (Kawasumi et al., 2004; Radde, Duma, 
Goedert, & Jucker, 2008). This makes mouse models relatively good models of amyloid 
deposition, but poor models of tau pathology and neuronal loss, which are key 
components of AD in humans.                                           
Another limitation of the amyloid cascade hypothesis is failure of therapeutics 
targeted against Ab pathology. AD treatments based on the amyloid cascade hypothesis 
act on steps along the cascade, attempting to inhibit APP processing, Ab deposition and 
aggregation, and other targets. Several clinical trials have attempted to use anti-Ab 
antibodies to decrease the amyloid burden in the brain and hopefully ameliorate some of 
the symptoms of AD. Despite some trials reducing the amyloid burden, they have been 
largely unsuccessful in ameliorating the clinical decline in cognition (DeMattos et al., 
2001; Munch & Robinson, 2002). The failure of drugs designed to decrease Ab levels to 
improve to outcomes in AD weakens the amyloid cascade hypothesis, particularly 
because some of those same drugs were successful in mice, further suggesting that these 
may be poor models of disease (Orgogozo et al., 2003; Serrano-Pozo et al., 2010). All of 
these issues detract from the notion that Ab is the primary driver of AD. Nevertheless, 
Ab is still a primary pathological hallmark of AD and a more complete understanding of 
its role is crucial for the advancement of the field.  
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Tau in Alzheimer’s Disease 
Amyloid is not the only pathological insult in the progression of AD pathology. 
Hyperphosphorylation of tau leads to the accumulation of NFTs within neurons leading 
to synaptic dysfunction, impaired cellular transport and cell death. Unlike Ab plaques, 
NFTs have been positively correlated with increasing severity of AD (Arriagada, 
Growdon, Hedley-Whyte, & Hyman, 1992; Arriagada, Marzloff, & Hyman, 1992). While 
the hyperphosphorylation of tau has been proposed as a central pathway in AD 
pathogenesis, tau pathology is likely augmented by Ab and other insults such as 
neuroinflammation.   
Tau is a cytoskeletal protein that associates with microtubules (G. Lee, Neve, & 
Kosik, 1989; Tucker, 1990). Within the axons of neurons are large amounts of 
microtubule tracts involved in the transport of vesicles from the cell body to the synaptic 
terminals. As a microtubule associated protein brain tau is predominately found within 
the axons of neurons (G. Lee et al., 1989; Tucker, 1990). Tau stabilizes the 
polymerization of these microtubules via its microtubule binding domain (G. Lee et al., 
1989; Reddy, 2011). Tau contains several regions that can be phosphorylated in order to 
regulate its binding affinity (Reddy, 2011). Phosphorylation of tau impairs its ability to 
bind microtubules; by decreasing the amount of tau bound to microtubules increases the 
amount of free phosphorylated tau (Mazanetz & Fischer, 2007; Raskin, Cummings, 
Hardy, Schuh, & Dean, 2015). This increased tau can either remain in a non-fibrillar form 
within the cytosol or self-assemble into paired helical filaments and straight filaments 
which aggregate into NFTs (Berriman et al., 2003). Hyperphosphorylated tau is less 
	  	  
 
11	  
soluble than the unphosphorylated form and more easily forms filaments and subsequent 
NFTs. It may also enhance the sequestration of normal tau into NFTs (Cowan, Bossing, 
Page, Shepherd, & Mudher, 2010; Reddy, 2011; Raskin et al., 2015). The 
hyperphosphorylation of tau is proposed to cause microtubule dysfunction leading to the 
accumulation of material within cells causing damage, loss of synapses, and 
neurodegeneration in conjunction with the accumulation of NFTs (Cash et al., 2003; Roy, 
Zhang, Lee, & Trojanowski, 2005; Li, Chohan, Grundke-Iqbal, & Iqbal, 2007).  
One of the major issues with tau being the primary driver of AD pathology is the 
absence of a factor that triggers initial tau hyperphosporylation. Unlike Ab, there is no 
clear genetic factor leading to abnormal tau production in AD. However a multitude of 
new single nucleotide polymorphisms (SNPs) associated with AD have been discovered 
that were previously masked in genome wide analysis studies by the effect of APOE (Jun 
et al., 2016). One of these SNPs occurs near the MAPT gene indicating a novel genetic 
mutation in tau leading to AD (Jun et al., 2016). Even with the discovery of genetic 
factors impacting tau in AD there is still a missing connection between tau and Ab 
pathologies.  
 
Neuroinflammation in Alzheimer’s Disease 
In recent years there has a been a resurgence in the study of neuroinflammation as 
pathogenic in AD. Neuroinflammation has been observed in AD but was initially thought 
to be a consequence of later stage Ab plaque accumulation. However, more recent data 
indicates that neuroinflammation may be involved much earlier in the disease process and 
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may play a role in the development of AD pathology (Tarkowski, Andreasen, Tarkowski, 
& Blennow, 2003). Much of the impetus for this shift in thinking was the discovery of 
variants of the gene encoding Triggering Receptor Expressed on Myeloid cells 2 
(TREM2) associated with an increased risk for AD (Jay, von Saucken, & Landreth, 
2017). TREM2 is a transmembrane protein expressed exclusively in immune cells and 
predominantly in microglia in the CNS (Jay et al., 2017). The discovery of a mutation 
leading to AD only on myeloid cells supports the hypothesis that neuroinflammation is 
not just a byproduct of AD pathology but a contributing factor. TREM2 is proposed to 
have an anti-inflammatory function, reducing both the activation of microglia and the 
release of pro-inflammatory cytokines (Turnbull et al., 2006; Zhang et al., 2017). This 
inhibitory effect of TREM2 may be altered in mutations associated with AD creating an 
unbalanced level of cytokines and an increased pro-inflammatory state that contributes to 
AD pathology (T. Jiang, Yu, Zhu, & Tan, 2013). While the prevalence of TREM2 
mutations is very rare, the insight gained from these mutations highlights unbalanced 
inflammation as a potential mechanism contributing to AD pathology (T. Jiang et al., 
2013). The involvement of neuroinflammation in AD is further supported by data 
indicating that cytokine levels are elevated in individuals with mild cognitive impairment 
(MCI), prior to widespread plaque development (Brosseron, Krauthausen, Kummer, & 
Heneka, 2014).  
Inflammation is not a static process and it is proposed to change over the course 
of AD. Neuroinflammation in AD may transition from an initial acute response where 
immune cells are activated and recruited to the site of injury to a chronic phase where the 
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initial stimulus, possibly Ab plaques, is not removed and a sustained level of 
inflammation is created. In AD, acute inflammation may have a beneficial impact, 
reducing the amyloid burden in the brain; while chronic neuroinflammation may sustain 
the pathologic state and even exacerbate some of the symptoms (Z. Cai, Hussain, & Yan, 
2014). In addition to changes in inflammation overall, microglia themselves exhibit 
varying phenotypes that can transition from relatively quiescent, to active, to overactive 
forms based on the surrounding microenvironment (Heppner, Ransohoff, & Becher, 
2015). Macrophages have previously been separated into classically and alternatively 
activated divisions due to selective activation from pro-inflammatory and anti-
inflammatory signals respectively, and microglia were thought to have a similar 
activation pattern (Heppner et al., 2015). However, in recent years an increasing number 
of macrophage activation states have been discovered and the bimodal activation theory 
is being replaced in favor a broad spectrum of activation (Martinez & Gordon, 2014; 
Heppner et al., 2015). Activated microglia release a plethora of cytokines and 
chemokines in response to different signals, which include cytokines and chemokines 
themselves. 
Microglia have a complicated role in the pathogenesis of AD. They are observed 
surrounding Ab plaques, and fibrillar Ab interacts with microglia inducing their 
transition to a more active phenotype and increasing their production of cytokines 
(Perlmutter, Barron, & Chui, 1990; Du Yan et al., 1997; Fassbender et al., 2004). Studies 
show on one hand microglia are able to decrease the amount of Ab through phagocytosis, 
but on the other hand their release of pro-inflammatory factors may be cytotoxic and 
	  	  
 
14	  
worsen Ab deposition and neuronal damage  (Thameem Dheen, Kaur, & Ling, 2007; 
Grathwohl et al., 2009; Venneti, Wiley, & Kofler, 2009; Z. Cai et al., 2014; Bagyinszky 
et al., 2017). Beyond interacting with Ab, microglia have also been observed associating 
around neurons with abnormally hyperphosphorylated tau (Ishizawa & Dickson, 2001; 
Gerhard et al., 2006). A recent study by Maphis et al. (2015) in mice expressing human 
tau found that microglia activation correlates with the spread of tau pathology and may be 
a potential driver of tauopathy. These results have also been observed in humans, with 
increased Iba1 microglia density surrounding neurons with tau pathology, as measured by 
the density of AT8 immunostaining (Sasaki et al., 2008). Microglia have been proposed 
to worsen tau pathology, however, tau may in turn lead to increased microglia activation 
(Uchihara et al., 1995; Sasaki et al., 2008; Maphis et al., 2015). Increased expression of 
tau in mice has been associated with increased Iba1 microglia density and altering the 
inflammation response at the transcription level (L. Wang et al., 2013; Wes et al., 2014). 
While it is unclear whether microglia activation drives worse tau pathology or tau 
pathology activates microglia, they may both be occurring. It is important to note that 
microglia activation promoting tau pathology is more supported in the literature 
(Yoshiyama et al., 2007). 
Many of the cytokines released by activated microglia are the same cytokines - 
IL-1, TNF-a, IFN-g, IL-6 - that are elevated in plasma and CSF of AD patients (Zheng, 
Zhou, & Wang, 2016). Over time, the detrimental influence of activated microglia and 
the chronic state of inflammation they perpetuate may overpower any beneficial effect. 
This is supported by the observation that the prolonged presence of Ab and cytokines 
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may actually impair the ability of microglia to phagocytose Ab (Hickman, Allison, & El 
Khoury, 2008; Krabbe et al., 2013). This impairment may lead to the development of 
dystrophic microglia that no longer function properly and subsequently burn out. The role 
of microglia may be mediated by the specific factors they release and the balance 
between pro-inflammatory and anti-inflammatory cytokines.  
 
Cytokines in AD 
Cytokines are large family of proteins that elicit a particular response from cells. 
Inflammatory cytokines are generally divided into pro-inflammatory and anti-
inflammatory divisions; however, those designations are not always accurate and may 
depend on the specific situation in which they are released. Many of the cytokines 
involved in AD - IL-6, IL-1b, IL-1a, TNF-a, IL-4, IL-12, IL-23, IFN-g - exhibit genetic 
polymorphisms that impart a small risk for developing AD (Arosio et al., 2004; H. K. 
Wang et al., 2007; Payao et al., 2012; Bagyinszky, Youn, An, & Kim, 2014; Zheng et al., 
2016). The true role of cytokines in AD is still under debate, as many studies find 
different, and often opposing, results when examining the impact of cytokines on AD 
pathology. Much of this variation arises from different study parameters, using different 
animal models, and different methods of cytokine administration; even post-mortem 
analysis of AD brains yields widely varying levels of cytokines (Tweedie et al., 2012; 
Zheng et al., 2016; Bagyinszky et al., 2017). 
Pro-inflammatory cytokines generally promote activation and recruitment of 
immune cells, including microglia, and the production of other inflammatory factors in 
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response to injury. Anti-inflammatory cytokines tend to have an opposing effect, 
decreasing the recruitment of microglia or promoting a less active phenotype. Anti-
inflammatory cytokines are often released at the same time as pro-inflammatory 
cytokines in order to temper the inflammatory response. The levels of many markers of 
inflammation change in AD; generally pro-inflammatory cytokines are increased and 
anti-inflammatory cytokines are decreased or show no change in levels. Reported levels 
and changes in cytokines vary in AD and may be due to the method of observation. 
Cytokines levels are shown to be elevated in the cerebrospinal fluid (CSF) and plasma of 
AD patients, but using the concentration in these locations to model the levels within the 
brain may not be entirely accurate (Brosseron et al., 2014). Cytokines may directly alter 
plaque pathology as they are observed co-localized within Ab plaques (Griffin et al., 
1989; Strauss et al., 1992; Hüll, Berger, Volk, & Bauer, 1996). However, it is also likely 
that they influence AD pathology indirectly through their regulatory effect on microglia 
and other immune cells.  
 
Pro-inflammatory factors 
Interleukin-6 (IL-6) is one of the most commonly elevated cytokines in AD, but is 
also increased in edema and fibrosis (Elmslie, Dow, & Ogilvie, 1991; Kaplin et al., 2009; 
Zheng et al., 2016). IL-6 is also elevated in individuals with MCI, suggesting that is has 
an early role in AD (Schuitemaker et al., 2009). IL-6, along with IL-1b, IL-1a, TNF-a, 
has been found co-localized around Ab plaques, and IL-6 has been observed deposited 
within the plaques themselves, indicating a positive association between them (Griffin et 
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al., 1989; Strauss et al., 1992; Hüll et al., 1996). IL-6 is also associated with increased tau 
hyperphosphorylation possibly through activating the CDK5/p35 kinase complex 
(Quintanilla, Orellana, Gonzalez-Billault, & Maccioni, 2004).  
Interleukin-1b (IL-1b) is a soluble cytokine that is elevated in AD (Bagyinszky et 
al., 2017). IL-1b, whose release may be increased by oligomeric Ab, is proposed to 
activate microglia and increase their phagocytic capability (Shaftel et al., 2007; Parajuli 
et al., 2013). Increased levels of IL-1b are associated with improved clearance of Ab by 
microglia and decreased Ab plaque burden as shown in several mouse studies (Shaftel et 
al., 2007; Ghosh et al., 2013; Cherry, Olschowka, & O'Banion, 2015). Alternatively, 
mouse studies also show increased IL-1b is related with increased hyperphosphorylation 
of tau, possibly acting through associated kinases (Kitazawa et al., 2011; Ghosh et al., 
2013).  
In the same IL-1 family as IL-1b, is Interleukin-1a (IL-1a), and while they are 
encoded by different genes they exhibit similar effects (Garlanda, Dinarello, & 
Mantovani, 2013). However, IL-1a exists in both membrane bound and in secreted 
soluble forms (Weber, Wasiliew, & Kracht, 2010). The change in IL-1a levels in AD are 
less well understood than IL-1b but may	  be decreased or unchanged in AD (Dursun et al., 
2015). IL-1a is expressed after tissue damage by microglia in order to meditate the 
immune response, shown by the accumulation of IL-1a positive microglia around 
plaques (Griffin et al., 1989; Luheshi, McColl, & Brough, 2009; Dursun et al., 2015). 
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Interferon-g (IFN-g) is secreted by immune cells and is proposed to promote the 
infiltration and activation of additional immune cells. The levels of IFN-g are altered in 
AD and MCI and most reports find they are increased (Zheng et al., 2016). There are 
conflicting reports as to the impact of IFN-g on AD pathology. Mouse studies have 
shown increased IFN-g to be associated with creating a pro-inflammatory environment 
and ameliorating Ab burden (Chakrabarty et al., 2010). Interestingly, increased IFN-g in 
transgenic mice expressing Ab and tau was shown to increase Ab but decrease tau 
(Mastrangelo, Sudol, Narrow, & Bowers, 2009).  
Tumor necrosis factor alpha (TNF-a) can be produced by microglia, astrocytes, 
and neurons and helps initiate the immune response and regulate its continued effect 
(Bagyinszky et al., 2017). In AD both the level of TNF-a and its role are unclear and 
exhibit mixed results. TNF-a may increase Ab as evidenced by mouse studies using anti-
TNF-a treatments that have resulted in decreased amyloid and tau pathology (Russo et 
al., 2012; Detrait, Danis, Lamberty, & Foerch, 2014; Gabbita et al., 2015). However, 
TNF-a may be beneficial early in the disease process by recruiting microglia and 
improving the clearance of Ab (Chakrabarty, Herring, Ceballos-Diaz, Das, & Golde, 
2011).  
 
Anti-inflammatory factors 
Overall the impact of anti-inflammatory cytokines is less well studied than pro-
inflammatory cytokines in relation to AD, especially in relationship to tau pathology 
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where there is a dearth of studies examining the impact of anti-inflammatory cytokines. 
Much of the proposed role of anti-inflammatory cytokines in AD is in their ability to 
diminish the negative effects of elevated pro-inflammatory cytokines and activated 
microglia. A key study by Szczepanik (2001) using primary murine and human cell line 
microglia revealed that the anti-inflammatory cytokines IL-10, IL-4, and IL-13 were able 
to reduce Ab induced activation of pro-inflammatory cytokines. Specifically, IL-10 
inhibited the release of IL-6, IL-1b, IL-1a, TNF-a, and a chemokine, MCP-1; while IL-4 
and IL-13 only inhibited the release of IL-6 and IL-1 (Szczepanik, 2001).  
Interleukin-10 (IL-10) as an anti-inflammatory cytokine dampens inflammation. 
Its release, similar to other anti-inflammatory agents, is triggered by pro-inflammatory 
cytokines and creates a feedback loop to keep inflammation under control (Magaki, 
Mueller, Dickson, & Kirsch, 2007). Most reports find that IL-10 levels are elevated in 
AD however its role is less agreed upon (Zheng et al., 2016). IL-10 decreases the degree 
of Ab induced pro-inflammatory cytokine release which is proposed to reduce some of 
the negative effects of the chronic neuroinflammation (Szczepanik, 2001). Increased 
neuronal IL-10 gene expression, via adeno-associated virus injection in a mouse model of 
Ab pathology, has been shown to improve neurogenesis and cognition (Kiyota et al., 
2012). Alternatively, mouse models also show that IL-10 knockout mice exhibit 
increased Ab clearance and improved cognition; additionally, expressing IL-10 was 
associated with opposite results, worsening Ab pathology (Chakrabarty et al., 2015; 
Guillot-Sestier et al., 2015).  
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Interleukin-4 (IL-4) has been shown to decrease the accumulation of microglia 
and Ab plaques resulting in cognitive improvements in some mouse models (Kiyota et 
al., 2010). However, the opposite results have also been reported in mouse models, with 
IL-4 associated with decreased Ab clearance (Shimizu, Kawahara, Kajizono, Sawada, & 
Nakayama, 2008).  These differing results may be impacted by the specific effect IL-4 
has on different microglia phenotypes. IL-4 has been shown to improve phagocytosis in 
only some subsets of microglia. IL-4 levels may be decreased in AD but further studies 
are required to confirm this change (Derecki et al., 2010). More research is required to 
gain a more complete understanding of how IL-4 impacts microglia function. Interleukin-
13 (IL-13) is closely related in both structure and function to IL-4 (Minty et al., 1993). 
However, the role of IL-13 in AD is largely unknown.  
In summary, the role of cytokines in AD pathology has yet to be fully understood, 
but they are certainly involved, directly, indirectly, or possibly both, in the pathogenesis 
of AD. The mixed impact of cytokines may be confounded by differing roles in early AD 
compared to late AD. Pro-inflammatory cytokines may initially ameliorate Ab burden via 
microglia phagocytosis. This protective role may become dysfunctional in later stage 
disease and result in perpetuating a neurotoxic chronic inflammatory state. Moreover, a 
normally protective association of cytokines with AD pathologies may not properly 
function in some genetically susceptible individuals. 
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APOE and Neuroinflammation 
The state of neuroinflammation also differs based on APOE genotype and the 
ApoE protein has been observed colocalized with both Ab plaques and nearby associated 
microglia (Uchihara et al., 1995). The presence of the APOE e4 allele is associated with 
increased inflammation, microglia activation, and damage to neurons. Studies using 
lipopolysaccharide (LPS), a potent promoter of the inflammatory response, in transgenic 
mice expressing human ApoE protein have revealed an increased release of pro-
inflammatory cytokines and decreased release of anti-inflammatory cytokines in e4 
positive mice (Guo, LaDu, & Van Eldik, 2004; Gale et al., 2014; Tai et al., 2015). 
Additionally, in vitro LPS stimulation of microglia also revealed increased levels of 
TNF-a, and decreased levels of IL-10 (Jofre-Monseny et al., 2007). These effects are 
may result from altered function of the ApoE4 protein. The ApoE protein is generally 
exhibits anti-inflammatory effects. In vitro studies revealed that administration of ApoE 
decreased microglia activation (Guo et al., 2004; Baitsch et al., 2011). This anti-
inflammatory effect of ApoE was supported by ApoE knockout mouse exhibiting 
increased glial cell activation and higher levels of inflammatory markers (LaDu et al., 
2001; Grainger, Reckless, & McKilligin, 2004). In an in vitro study using cell cultures of 
neurons and glial cells in the same proportions as in human brain tissue there was 
increased neuronal damage and pro-inflammatory cytokine levels following LPS 
administration in tissue expressing ApoE4 compared to ApoE3 (Maezawa, Nivison, 
Montine, Maeda, & Montine, 2006).  
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The direct impact of APOE e4 on neuroinflammation in humans is less clear. 
Studies examining human post-mortem brain tissue found an increased number of 
microglia within AD patients with e4 (Overmyer et al., 1999; Egensperger, Kösel, Eitzen, 
& Graeber, 2006). A study by Minett et al. (2016) found microglia were negatively 
associated with AD pathology in non-demented individuals while the opposite was 
observed in demented individuals. Furthermore, this study found that e4 was associated 
with increased microglial activation and worse tau pathology and clinical outcomes 
(Minett et al., 2016). These studies highlight a negative impact of the APOE e4 allele 
leading to an altered immune state and worse AD pathology. The associations of APOE 
genotype and protein levels with inflammatory cytokines in the human brain though are 
largely unknown.      
While it is unclear what the driving mechanism for AD pathology is, Ab and 
NFTs disturb brain homeostasis and alter the activity of immune cells within the CNS. 
These altered immune cells may in turn play a role in perpetuating worsening pathology 
and maintaining a state of chronic neuroinflammation. We hypothesize that the presence 
of the APOE e4 allele negatively influences the interaction between microglia and Ab 
and tau pathology, expanding previous research in mouse and in vitro studies to 
postmortem human tissue. To assess these relationships, we examined brain tissue of 186 
participants of a community based aging cohort.   
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METHODS 
In the present study, we examined 186 autopsy participants from the Framingham 
Heart Study (FHS). The FHS is a community-based cohort that longitudinally tracks 
subjects over several generations. Participants who agreed to brain donation were 
enrolled and tissue was collected after death. Brains were evaluated for 
neurodegenerative diseases utilizing prior existing protocol and procedures  (Montine et 
al., 2012). Institutional review boards from both the Boston University Medical Center 
and the Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, approved brain 
donation. The Boston University Medical Center IRB also granted approval for post-
mortem clinical record review, neuropathological evaluation, and clinical interviews with 
donor family members.  
 
Pathological Assessment  
Neuropathological assessment was performed following procedures and criteria 
previously established by the VA-BU-CLF brain bank (Vonsattel, Del Amaya, & Keller, 
2008; Mez et al., 2015). Alzheimer’s disease was diagnosed based on the National 
Institute of Aging Reagan criteria. Alzheimer’s disease staging was performed according 
to the Braak and Braak staging for neurofibrillary tangles and the Consortium to 
Establish a Registry for Alzheimer's Disease (CERAD) semi-quantitative criteria for 
neuritic plaques. Braak stage I is defined as a low number NFTs present in the 
transentorhinal cortex; stage II includes NFTs in the entorhinal cortex; stage III includes 
the basal medial temporal lobe including the CA1 region of the hippocampus; stage IV 
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includes NFTs in the insular and basal neocortices; stage V includes NFTs in the 
prefrontal cortex and the sensory association neocortices; in stage VI NFTs extend to the 
primary motor and sensory cortices (Braak & Braak, 1991). CERAD staging classified 
the extent of neuritic plaque deposition within the middle frontal, superior/middle 
temporal, and inferior parietal cortices as sparse, moderate, or frequent (Mirra et al., 
1991). Neuritic plaques were defined as plaques with argyrophilic dystrophic neurites, 
with or without dense amyloid cores (Montine et al., 2012).  
 
Immunohistochemistry  
Tissue was fixed in periodate-lysine-paraformaldehyde, tissue blocks were 
paraffin-embedded, and sections were cut at 10µm for immunohistochemistry. Antigen 
retrieval for α-synuclein and b-amyloid was performed with formic acid treatment for 
two minutes. Sections were incubated overnight at 4°C with antibodies to α-synuclein 
(rabbit polyclonal; Chemicon, Temecula, CA; 1:15,000), phosphorylated PHF-tau (AT8; 
Pierce Endogen, Rockford IL; 1:2000), Aβ (4G8; BioLegend, San Diego, CA; 
1:100,000), and pTDP-43 (pS409/410 mouse monoclonal; Cosmo Bio Co, Tokyo, Japan; 
1:2000). Sections were washed three times with phosphate-buffered saline (PBS; pH 7.4), 
and subsequently treated with biotinylated secondary antibody and labeled with a 3-
amino-9-ethylcarbazol HRP substrate kit (Vector Laboratories, Burlingame, CA). The 
sections were then counterstained with Gill’s Hematoxylin (Vector Laboratories H-3401, 
Burlingame, CA) and subsequently coverslipped using Permount mounting medium. 
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ELISA Measurement   
Frozen tissue from the dorsolateral frontal cortex was weighed and placed on dry 
ice. Freshly prepared, ice cold 5M Guanidine Hydrochloride in Tris-buffered saline (20 
mM Tris-HCl, 150 mM NaCl, pH 7.4) containing 1:100 Halt protease inhibitor cocktail 
(Thermo Fischer Scientific, Waltham, MA) and 1:100 Phosphatase inhibitor cocktail 2 & 
3 (Sigma-Aldrich, St. Louis, MO) was added to the brain tissue at 5:1 (5M Guanidine 
Hydrochloride volume (ml):brain wet weight (g)) and homogenized with Qiagen Tissue 
Lyser LT at 50Hz for five min. The homogenate was then stored (regular rocker) 
overnight at room temperature. The lysate was diluted with 1% Blocker A (Meso Scale 
Discovery (MSD), catalog number #R93BA-4) in wash buffer according to specific 
ELISA assays: 1:4000 for alpha-synuclein (MSD #K151TGD-2), 1:300 for total tau and 
pTau231 (MSD #K15121D-2), and 1:4000 for beta-amyloids 1-40 and 1-42 
(MSD #K15200E-2). Samples were subsequently centrifuged at 17,000g and 4°C for 15 
minutes, after which the supernatant was applied to the ELISA assays.  
Hypothesis driven cytokines, IFN-g, IL-1b , IL-4, IL-10, IL-13, TNF-a, and IL-
1a, from the MSD Proinflammatory Panel 1 and Cytokine Panel 1 microplates of the 
Neuroinflammation Panel 1 were analyzed. Cytokine ELISA measurement was 
preformed according to MSD protocol using sandwich immunoassay techniques. Brain 
tissue was diluted with MSD diluent 21 and incubated for 2 hours with shaking at 500 
rpm and subsequently washed three times with PBS + 0.05% Tween-20. Cytokine 
antibody was then added and the mixture was incubated for 2 hours with shaking at 500 
	  	  
 
26	  
rpm, and again subsequently washed three times with PBS + 0.05% Tween-20. 2X Read 
buffer T (MSD #R92TC-3) was added prior to analysis. Sulfo-tag conjugated anti-mouse 
secondary antibody was used for signal detection by the MSD platform, and an MSD 
SECTOR Imager 2400 was used to measure analyte levels. 
 
Microscopic Analysis of Tau and Microglia Density  
Tissue blocks from the dorsolateral frontal cortex were embedded in paraffin and 
cut at 10µm. Slides immunostained for tau (AT8), activated microglia (CD68), and 
microglia overall (Iba1) were scanned at 20x magnification with a Leica Aperio 
Scanscope (Leica Biosystems, Buffalo Grove, IL) as previously described (Cherry et al., 
2016). Briefly, using ImageScope (Leica Biosystems, Buffalo Grove, IL), the gray matter 
was highlighted from the pia to the boundary between the white and gray matters. Leica’s 
image analysis and automated counting software (Aperio nuclear algorithm, Version 9) 
was calibrated for shape, size, and staining intensity to detect AT8-immunoreactive 
NFTs, CD68-immunoreactive cells, and Iba1-immunoreactive cells within the region of 
interest. Counts were normalized to the area measured and are presented as density within 
the analyzed region. Tau and microglia densities were only used from gyri and not from 
the sulci in order to avoid possible contributions from CTE.  
 
Statistical Analysis  
Statistical analysis was performed with SPSS version 24.0 (IBM inc., Armonk, 
NY) Prism v7 (Graphpad Software, La Jolla, CA). To assess the variance between APOE 
	  	  
 
27	  
e4 carrier and non-carrier groups with respect to demographic and neuropathological 
characteristics we applied a chi-square test for proportions.  
Prior to linear regression analysis, data was normalized and outliers were 
removed. Outliers were defined by values 2.2 times the interquartile range away from the 
mean for each group. Ab1-42 data was still not normally distributed after log or square 
root corrections and removing outliers, and therefore Ab1-42 values were divided into 
quartiles and used as an ordinal variable. In order to allow comparison, Ab1-40 values 
were analyzed as quartiles as well. To evaluate the mean differences between APOE e4 
positive and negative groups, we applied a t-test. Multiple linear regression analyses were 
used to examine relationships between microglia, cytokines, and markers of AD 
pathology, controlling for age, sex, and APOE e4 allele frequency. 
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RESULTS 
Of the 186 participants from the FHS cohort analyzed there were 140 with no 
APOE e4 allele and 46 carrying the e4 allele. These two groups varied significantly by 
frequency of AD, cerebral amyloid angiopathy (CAA), and the absence of any significant 
pathology (control; Table 1). The APOE e4 carriers group had a higher prevalence of AD  
Table 1: Demographic and neuropathological characteristics of FHS cohort 
  FHS   e4 Allele Absent e4 Allele Present p value  
Sample size (n) 186 140 46 - 
Age at Death 
(yrs) 86.85 (.673) 87.14 (.787) 85.98 (1.298) 0.387 
Sex (% male) 45.50% 44.30% 48.90% 0.59 
AD 35.10% 27.30% 58.70% <0.001 
CTE 1.70% 1.10% 3.40% 0.389 
LBD 27.00% 26.60% 28.30% 0.828 
Neocortical LBD 7.60% 7.90% 6.50% 0.757 
FTLD 9.20% 9.20% 9.10% 0.978 
Control 16.20% 19.50% 6.70% 0.011 
Cortical 
Microinfarcts 42.20% 44.40% 35.60% 0.296 
Large Infarcts 20.60% 18.30% 27.50% 0.223 
Arteriolosclerosis 55% 53.60% 60.00% 0.455 
Atherosclerosis 38.10% 39.10% 35% 0.638 
CAA 25.70% 17.10% 51.20% <0.001 
Age values are presented as mean (S.E.M.); FHS: Framingham Heart Study; LBD: Lewy 
body disease; AD: Alzheimer’s disease; CTE: Chronic Traumatic Encephalopathy; 
FTLD: Frontotemporal Lobar Degeneration; CAA: Cerebral Amyloid Angiopathy; 
Control participants were those lacking significant pathology; Pathology prevalence 
represent the presence of pathology not the primary diagnosis; *c2 test for proportions 
between e4 allele absent and present groups. 
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and CAA pathology, while the group lacking e4 consisted of more control individuals. 
To further examine differences between e4 positive and negative groups we 
compared the mean differences of variables of interest. As expected Ab1-42 and Ab1-40 
levels were significantly higher in e4 positive individuals than in those without the e4 
allele (453.7 ± 145.3, p = 0.0021; 158.4 ± 36.2, p < 0.0001; difference between means ± 
SEM, t-test), while AT8 levels were higher in e4 positive individuals than e4 negative 
individuals, but not significant (8963 ± 8133, p = 0.2721; difference between means ± 
SEM, t-test). Additionally, Iba1 and CD68 microglia density, ApoE protein, and all 
examined cytokine levels were not significantly different between e4 positive and 
negative groups. These mean comparisons do not account for other factors that may 
contribute to AD pathology, including but not limited to age and sex, which may 
contribute to the lack of significant differences. In order to account for these factors, we 
performed multiple linear regression analyses.  
 
Relationship between Microglia and AD Pathological Markers 
We hypothesized that the density of microglia would be related to both amyloid 
and tau pathology. Multiple linear regression analysis showed that Ab1-40, but not Ab1-42 
was significantly associated with Iba1 microglia density (b = 0.185, p = 0.019) 
controlling for age, sex, and APOE e4 allele frequency. A separate multiple linear 
regression analysis showed that tau pathology as measured by density of AT8 
immunostaining was significantly related to Iba1 microglia density (b = 0.179, p = 0.025) 
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controlling for age, sex, APOE e4 allele frequency, and Ab1-42. No measures of AD 
pathology were significantly associated with CD68 overall.   
To test the hypothesis that the presence of the APOE e4 allele altered the 
relationship between microglia and amyloid and tau pathology we examined these 
associations separately in participants with and without the e4 allele. We initially used 
scatter plots subdivided in e4 positive and negative groups to examine the relationship of 
microglia with AD pathology (Figure 1). While there were apparent differences between 
APOE e4 allele positive and negative groups the scatter plots do not control for additional 
factors contributing to amyloid and tau pathology. Considering this, multiple linear 
regression analyses were used to account for these contributing factors (Table 2). 
Multiple linear regression analysis revealed a significant negative relationship of Ab1-42 
with Iba1 microglia density only in e4 positive participants (b = -0.358, p = 0.05) 
controlling for age and sex. A similar test showed a positive relationship of Ab1-40 with 
Iba1 in e4 only positive individuals (b = 0.46, p = 0.035) controlling for age and sex. A 
multiple linear regression showed a significant positive association of tau pathology with 
Iba1 positive microglia, again only in e4 positive participants (b = 0.459, p = 0.028) 
controlling for age, sex, and Ab1-42. Multiple linear regression analysis of amyloid and 
tau pathology with CD68 did not exhibit any significant relationships. However, there 
was a trending toward significant relationship of Ab1-42 with CD68 in e4 positive 
participants (b = -0.316, p = 0.063) controlling for age and sex. There is a clear difference  
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Figure 1: APOE ε4 allele alters the 
relationship between Iba1 and AD 
Pathology. Scatter plots of Iba1 
predicting AT8, Aβ1-42, and Aβ1-40!
values are shown (A, B, C, respectively). 
The FHS cohort is divided into APOE ε4 
positive and negative groups (Red 
squares and blue circles respectively). 
Linear regressions were run to assess the 
different trends between APOE ε4 
positive and negative groups. A) Iba1 
displayed significant positive 
relationship with AT8 but only in ε4 
positive participants 
(β = 0.379, p = 0.016). B) Iba1 displayed 
significant negative relationship with 
A1-42 in ε4 positive participants 
(β = -0.325, p = 0.046) and non-
significant positive association with 
Aβ1-42 in ε4 negative participants 
(β = 0.145, p = 0.107). C) Iba1 displayed 
significant positive relationship with 
Aβ1-40 in ε4 positive and ε4 negative 
participants (β = 0.381, p = 0.038; 
β = 0.187, p = 0.044). Note that these 
linear regressions were run without 
controlling for possible driving factors. 
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in the relationship of Iba1, but not CD68, with AD pathology depending on the presence 
of the APOE e4 allele. These results suggest that within e4 negative individuals, 
microglia do not contribute to AD pathology. However, within e4 positive individuals, 
microglia exhibit mixed effects possibly decreasing Ab1-42 and at the same time 
increasing Ab1-40 and tau pathology. 
 
Relationship Between Cytokines and AD Pathological Markers 
To determine if cytokine interactions were underlying the interaction between 
microglia and pathologic markers, linear regressions were also used to assess the impact 
of select cytokines on Ab pathology controlling for age and sex in e4 positive and 
negative individuals (Table 3). We hypothesized that both pro-inflammatory and anti-
inflammatory cytokines would display a negative or a nonsignificant association with AD 
pathology in e4 negative participants. While in e4 positive participants, we hypothesized 
that pro-inflammatory cytokines would instead display a positive association with 
amyloid and tau pathology due to an altered state of inflammation. Analyses for each 
cytokine were run independent of other cytokines in order to avoid collinearity issues. 
Within e4 negative participants, multiple linear regression analysis showed a significant 
negative association of Ab1-42 with IL-1b (b = -0.234, p = 0.006) controlling for age and 
sex. A separate multiple linear regression showed a significant negative association of 
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Ab1-42 with TNF-a in e4 negative participants (b = -0.202; p = 0.019) controlling for age 
and sex. Additionally, multiple linear regression analysis revealed a significant 
association of Ab1-40 with TNF-a in e4 negative participants (b = -0.196, p = 0.011) 
controlling for age and sex. Only the relationship between Ab1-42 and IL-1b survived a 
Bonferroni correction for multiple comparisons. Regression analysis showed no 
significant relationship between Ab1-42 and anti-inflammatory cytokines in e4 negative 
participants (Table 3). However, there was a trend toward a significant relationship 
between Ab1-42 and IL-4 in e4 negative participants (p = 0.059) controlling for age and 
sex.  
Table 3: Multiple Linear Regressions Associating Ab1-42 with 
Cytokines in APOE e4 Positive and Negative Groups  
 
e4 Negative e4 Positive 
  b P Value b P Value 
IL-10 0.073 0.395 0.502 0.002* 
IL-13 0.048 0.579 -0.014 0.932 
IL-4 0.161 0.059 0.48 0.002* 
TNF-a -0.202 0.019 -0.215 0.209 
IL-1b -0.234 0.006* 0.301 0.094 
IL-1a -0.086 0.325 0.054 0.762 
IFN-g 0.091 0.291 0.494 0.004* 
 
 
Within e4 positive participants, a multiple linear regression showed a positive 
association of Ab1-42 with IFN-g (b = 0.494, p = 0.004) controlling for age and sex. 
Multiple linear regression analysis also showed a significant positive association of Ab1-
   * = p < 0.05 after Bonferroni correction for multiple comparisons. 
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42 with IL-10 in e4 positive participants (b = -0.502, p = 0.002) controlling for age and 
sex. A separate multiple linear regression showed a similar significant positive 
association of Ab1-42 with IL-4 (b = 0.48; p = 0.002) controlling for age and sex. The 
associations of Ab1-42 with IFN-g , IL-10, and IL-4 within e4 positive participants were 
each still significant after a Bonferroni correction for multiple comparisons. Controlling 
for ApoE protein levels did not significantly alter the association of cytokines with Ab1-42 
or Ab1-40. Because high levels of IL-1b and TNF-a are associated with less Ab1-42 in e4 
negative participants, these cytokines may have a protective effect on Ab accumulation 
that is lost in e4 positive individuals. In contrast, high levels of IL-10, IL-4, and IFN-g 
were associated with increased Ab, suggesting an altered cytokine response within e4 
positive individuals.  	   To test the hypothesis that cytokine associations with tau pathology were altered 
by the presence of APOE e4, we performed multiple linear regression analyses 
controlling for age and sex (model 1; Table 4). In e4 negative participants, IL-10, IL-13, 
IL-4, and IL-1a were all significantly negatively associated with AT8 tau pathology. 
Only the relationship between AT8 tau pathology and IL-10 remained significant after a 
Bonferroni correction for multiple comparisons. In a separate model (model 2) 
controlling for age, sex, and total ApoE protein levels, the associations of IL-10, IL-13, 
and IL-4 were eliminated or reduced, suggesting that ApoE levels mediate these effects. 
In e4 positive participants, the associations of IL-10, IL-13, and IL-1a with tau pathology 
were not present; however, IL-4 was still trending towards a significant negative 
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relationship (b = -0.366, p = 0.067; Table 4). Interestingly, within e4 negative individuals 
the associations exhibited by the anti-inflammatory cytokines – IL-10, IL-13, IL-4 – were 
lost when controlling for ApoE protein levels, while IL-1a continued to display a 
significant negative relationship with AT8 independently of Ab1-42 and ApoE levels (b = -
0.27, p = 0.039). These results suggest a possible protective effect of cytokines on tau 
pathology in e4 negative individuals that may be mediated by ApoE protein levels. 
 
 
Relationship Between Cytokines and Iba1 Microglia Density 
In order to test the association between microglia and three of the most 
significantly changed cytokines (IL-10, IL-4, and IL-1a), linear regressions were 
performed controlling for age and sex (model 1); and age, sex, and ApoE protein levels 
(model 2; Table 5). Within e4 negative participants, IL-4 displayed a significant 
 
 
 
 
Model 1 was run controlling for age and sex; Model 2 was run controlling for age, sex, and 
ApoE protein levels. * = p < 0.05 after Bonferroni correction for multiple comparisons.  
 
Table 4:  Multiple Linear Regressions Associating AT8 with Cytokines in APOE !4 Positive 
and Negative Groups 
 !4 Negative !4 Positive 
 Model 1 Model 2 Model 1 Model 2 
 " p Value " p Value " p Value       "       p Value 
IL-10 -0.262 0.004* -0.091 0.466 -0.098 0.647 -0.224 0.505 
IL-13 -0.218 0.018 -0.153 0.22 -0.185 0.316 -0.126 0.626 
IL-4 -0.212 0.023 -0.071 0.565 -0.366 0.067 -0.405 0.143 
TNF-# 0.016 0.87 -0.174 0.179 0.135 0.484 -0.063 0.829 
IL-1" -0.106 0.274 -0.124 0.337 0.026 0.896 -0.256 0.36 
IL-1# -0.241 0.009 -0.27 0.039 -0.011 0.955 0.109 0.664 
IFN-$ -0.082 0.375 -0.035 0.781 -0.207 0.365 -0.432 0.228 
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association with Iba1 microglia density (b = -0.189, p = 0.036). This relationship was lost 
when controlling for ApoE levels, suggesting that the association between IL-4 and Iba1 
microglia density is mediated by total ApoE protein levels. IL-4 also showed a negative 
relationship with Iba1 microglia density in e4 positive participants (b = -0.264, p = 0.083) 
which became stronger and significant when controlling for ApoE levels (b = -0.422,      
p = 0.044). IL-10 also displayed a significant negative association with Iba1 microglia 
density in e4 positive participants (b = -0.308, p = 0.046) that became stronger when 
controlling for ApoE levels (b = -0.472, p = 0.036). Conversely, IL-la exhibited a 
significant positive association with Iba1 microglia density in e4 positive participants    
(b = 0.394, p = 0.01) that was significant after a Bonferroni correction for multiple 
comparisons, however, this effect was lost when controlling for ApoE levels. The 
significant relationships of IL-10 and IL-la with Iba1 microglia density in e4 positive 
individuals were not observed in the absence of e4. Overall, increased levels of the anti-
inflammatory cytokines IL-10 and IL-4 were associated with decreased microglia density 
and the pro-inflammatory cytokine IL-1a was associated with increased microglia density 
in e4 positive participants.  
 
Sensitivity Analysis 
In order to control for possible confounds additional analyses were performed 
controlling for comorbid pathologies – cerebral amyloid angiopathy, cortical 
microinfarcts, arteriolosclerosis, atherosclerosis, and neocortical Lewy bodies – and did 
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not significantly alter the results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Model 1 was run controlling for age and sex; Model 2 was run controlling for age, sex, and 
ApoE protein levels. * = p < 0.05 after Bonferroni correction for multiple comparisons 
 
Table 5: Multiple Linear Regressions Associating Iba1 with Cytokines in APOE !4 Positive and 
Negative Groups 
 !4 Negative !4 Positive 
 Model 1 Model 2 Model 1 Model 2 
 " p Value " p Value " p Value " p Value 
IL-10 -0.048 0.599 -0.044 0.714 -0.308 0.046 -0.472 0.034 
IL-4 -0.189 0.036 0.037 0.76 -0.264 0.083 -0.422 0.044 
IL-1# -0.145 0.11 0.011 0.925 0.394 0.01* 0.209 0.304 
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DISCUSSION 
 
In this study, we examined brain tissue of 186 participants from the Framingham 
Heart Study (FHS), a community based aging cohort, in order to assess the relationship 
between microglia, associated cytokines, and AD pathology. Our analysis revealed that 
these relationships were significantly altered by the APOE e4 allele. Higher levels of 
cytokines, IL-10, IL-13, IL-4, and IL-la, were associated with decreased tau pathology as 
measured by density of AT8 immunostaining within e4 negative participants. The 
relationships of anti-inflammatory cytokines, IL-10, IL-13, IL-4, but not IL-1a,  and tau 
pathology were weakened when controlling for ApoE protein levels, suggesting the ApoE 
protein is involved in the interaction of anti-inflammatory cytokines with tau pathology. 
In e4 positive participants associations between cytokines and tau pathology were not 
present. Furthermore, higher Iba1 microglia density was associated with increased tau 
pathology in e4 positive participants. Compared to participants without the e4 allele, the 
associations of inflammation and tau pathology within e4 carriers suggest the loss of a 
possible protective function of cytokines contributing to the association of microglia with 
increased tau pathology.  
 
Implications for Amyloid Pathology 
Microglia have been shown to have a mixed impact on Ab pathology, both 
increasing and decreasing the deposition of Ab in different situations. We also observed 
opposing roles for microglia within e4 positive individuals on different forms of Ab; Iba1 
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cellular density was related to decreased Ab1-42 and increased Ab1-40. This difference 
between Ab isoforms may be due a variety of factors. A previous post-mortem study of 
patients with AD revealed that Ab1-40 in plaques was increased, even more than Ab1-42, in 
individuals with the APOE e4 allele compared to those without the allele (Mann et al., 
1997). A similar study examining non-demented individuals found that the presence of e4 
deposition of Ab1-42 at an earlier age followed by increased Ab1-40 deposition later in life 
(Walker et al., 2000). Impairment of microglia phagocytic ability has been correlated 
with increased amyloid deposition (Krabbe et al., 2013). Therefore, our finding that 
increasing Iba1 cell density was associated with lower levels of Ab1-42 but higher levels 
of Ab1-40 may suggest a selective phagocytosis of Ab1-42 by microglia in e4 positive 
participants.  
Our results support previous work in mouse models of Ab pathology that 
demonstrated IL-1b and TNF-a decrease Ab1-42 burden, and expands upon previous work 
by showing that this protective effect of IL-1b and TNF-a is present only in e4 negative 
participants (Shaftel et al., 2007; Chakrabarty et al., 2011; Ghosh et al., 2013; Cherry et 
al., 2015). These significant negative associations with Ab1-42 were lost in e4 positive 
participants and instead we observed positive associations of cytokines, IFN-g, IL-10, IL-
4, with Ab1-42 (Table 3). IFN-g, IL-10, and IL-4 have been proposed to increase amyloid 
deposition in mouse models of Ab pathology, supporting our findings; however they 
have also been associated with decreasing Ab levels (Mastrangelo et al., 2009; Kiyota et 
al., 2010; Chakrabarty et al., 2015; Guillot-Sestier et al., 2015). We hypothesize that the 
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difference between cytokine interactions with Ab1-42 in e4 positive and negative 
participants reflect an immune state that has an altered and detrimental function in the 
presence of e4. Studies in transgenic mice have shown an increased level of pro-
inflammatory cytokines and microglial activation in mice expressing human ApoE4; 
specifically, IL-1b and TNF-a were increased in e4 expressing mice (Maezawa et al., 
2006; Rodriguez, Tai, LaDu, & Rebeck, 2014; Tai et al., 2015). While we did not observe 
a significant difference in microglia or cytokines levels between e4 positive and negative 
groups, the FHS cohort is a heterogeneous group of varying age, sex, and degrees of 
pathology, which are not accounted for by comparing the means of the two groups. It is 
interesting that both IL-1b and TNF-a are related to the presence of the e4 allele and their 
negative association with Ab1-42 in the absence of e4 is lost in e4 positive participants. 
This may be due to altered interactions of cytokines in e4 carriers, independent of an 
overall change in their levels. While the precise mechanisms involved are not clear, it is 
apparent that presence of the APOE e4 allele negatively influences the relationship of 
inflammation and Ab pathology.  
 
Implications for Tau Pathology 
Microglia have been proposed to worsen tau pathology and to be toxic to neurons  
(Uchihara et al., 1995; Sasaki et al., 2008; Maphis et al., 2015). The reciprocal 
relationship, that tau induces microglial activation, has also been suggested based on 
findings in mice that expression of tau increases the number Iba1 microglia density and 
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also alters the expression of genes involved in inflammation (L. Wang et al., 2013; Wes 
et al., 2014). Our study supports the interaction of microglia and tau pathology as 
evidenced by the association of Iba1 microglia density with tau pathology overall and 
specifically within e4 positive individuals. While our study does not provide evidence for 
whether tau or microglia is the initial insult, it shows that the relationship is influenced by 
APOE. A previous post-mortem human study examining the middle frontal cortex, a 
region similar to the one examined in the current study, also found that Iba1 microglia 
density was significantly associated with tau pathology, however this was within 
individuals with dementia rather than the e4 allele (Minett et al., 2016). This study also 
found that Iba1 microglia density were associated with less tau pathology within non-
demented individuals (Minett et al., 2016). While these results align with our findings, 
Minett et al. (2016) also found that the e4 allele was associated with decreased Iba1 and 
increased CD68 positive microglia, which is not supported by our results. It is possible 
this discrepancy is the result of our study being underpowered. Only 46 participants in 
our study carried the e4 allele while the number of e4 carriers in the study by Minett et al. 
was not published.  
The relationship between microglia and tau pathology has also been reported in 
transgenic mouse studies expressing tau and APOE, finding that expression of e4 was 
associated with increased tau phosphorylation (Tesseur et al., 2000). An e4 specific 
impact of microglia on tau has also been observed within primary mouse tissue 
expressing APOE, revealing that microglia mediated cell damage was greater in e4 
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expressing mice than e3 or e2 (Maezawa et al., 2006). The previous study also proposes 
that the interaction between microglia and cell damage is mediated by the p38 mitogen 
activated protein kinase, which has been shown to phosphorylate tau (Reynolds, Betts, 
Blackstock, Nebreda, & Anderton, 2002; Maezawa et al., 2006). Our study supports these 
findings indicating that the role of microglia in tau pathology is detrimentally impacted 
by the presence of APOE e4 allele.  
This detrimental effect of microglia in the presence of e4 may be due in part to the 
loss of potentially protective cytokine interactions. Increasing levels of IL-10, IL-13, IL-
4, and IL-1a were associated with decreased tau pathology in e4 negative participants, 
while this effect is largely reduced in e4 positive participants (Table 4). There is a current 
lack of studies examining the role of anti-inflammatory cytokines in tau pathology. Most 
of the limited studies regarding the impact of anti-inflammatory agents examine 
exogenous drugs for AD treatment rather that endogenous cytokines involved in AD 
pathogenesis. An in vitro study examining a neuroblastoma cell line found that 
administration of IL-10 to cell culture prior LPS stimulation reduced the ability of 
microglia to stimulate expression of tau in neuroblastoma cells (M. Lee, McGeer, & 
McGeer, 2015). While this study does not directly correspond to AD due to the different 
cell types and the transient exposure of IL-10 rather than chronic inflammation in AD, it 
provides some limited evidence for a possible protective role of anti-inflammatory 
cytokines on tau pathology. 
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While the associations of IL-10 and IL-13 with tau pathology are diminished in 
the presence of e4, IL-4 displays a strong relationship with tau pathology in e4 positive 
participants that is nearly significant. This relationship may not be significant due to the 
limited number of e4 carriers in our cohort. This suggests that increasing IL-4 may 
continue to be associated with decreased tau pathology independent of APOE genotype. 
Further investigation is required to understand the impact of anti-inflammatory cytokines 
on tau pathology but based on our findings they may have a protective role that appears 
to be partially dependent on APOE genotype. 
Unlike the anti-inflammatory cytokines, increased IL-1a was significantly 
associated with decreased tau pathology independent of both Ab1-42 and ApoE protein 
levels within e4 negative participants. IL-1a in its membrane bound form has been 
observed on activated microglia colocalized with Ab plaques and neurons laden with tau 
pathology (Griffin et al., 1989; Sheng, Mrak, & Griffin, 1998). A previous study by 
Sheng et al. (1998) examining post-mortem tissue of 11 dementia patients found that    
IL-1a positive microglia positively correlated with the extent of NFT deposition within 
neurons. These results contradict our finding that increased IL-1a in e4 negative 
individuals is associated with less tau pathology, however the differences may be 
influenced by the different groups examined. Our study examined 186 participants of 
varying disease states, while the study by Sheng et al. only consisted of 11 participants, 
all with dementia. While our results differ from previous findings, membrane bound IL-
1a may still indicate a specific phenotype of microglia that could be used in future 
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studies to identify microglia involved in ameliorating AD pathology in e4 negative 
individuals. This is supported by our finding that increasing IL-1a levels were associated 
with increased Iba1 microglia density within e4 positive participants.   
 CD68 was not significantly related with any markers of AD pathology. While this 
was unexpected, it provides interesting insight into the diversity of the immune response. 
CD68, which is generally increased in AD, labels lysosomal proteins in activated 
microglia indicating increased phagocytic activity (Rabinowitz, 1991; Minett et al., 
2016). Even though CD68 was not significantly related to AD pathology, it was trending 
to towards a significant negative association with Ab1-42 in e4 positive participants (Table 
2). This might indicate a phagocytic effect of CD68 positive microglia on Ab1-42. The 
lack of a significant relationship between CD68 positive microglia and AD pathology, 
while the overall density of microglia does, suggests an alternative phenotype of 
activated microglia are involved in AD, particularly in tau pathology. This observation is 
supported by previous analysis of post-mortem tissue finding no association between 
CD68 and Iba1 labelled microglia, suggesting different populations of microglia within 
the brain (Minett et al., 2016). The same study also found several other microglial 
markers significant related to AD pathology supporting the diverse nature of microglia 
phenotypes involved in AD pathology in humans (Minett et al., 2016).  
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Role of the ApoE Protein  
The negative relationship between anti-inflammatory cytokines, IL-10, IL-13, and 
IL-4, and tau pathology was lost when controlling for ApoE protein levels, indicating that 
the effect of anti-inflammatory cytokines on tau pathology within e4 negative individuals 
may be mediated by ApoE protein levels (Table 4). APOE is proposed to have an anti-
inflammatory role that is in part due to specific interactions of the ApoE protein with 
microglia (Guo et al., 2004; Tai et al., 2015). ApoE protein levels also altered the 
relationship of cytokines and Iba1 positive microglia (Table 5). Increased IL-1a was 
associated with increased Iba1 microglia density only within e4 positive participants. 
This relationship was weakened when controlling for ApoE protein levels, indicating its 
possible role in the propagating an increased inflammatory response in the presence of 
e4.  
Altered ApoE protein function is a possible mechanism for observed differences 
between APOE e4 allele carriers. However, whether the ApoE4 protein imparts a toxic 
gain of function or perhaps the loss of a protective function is under debate. To greater 
understand the role of the ApoE protein, the impact of LPS and Ab stimulated 
inflammation has been examined in transgenic mice expressing APOE e2, e3, e4, or no 
APOE. This study found the highest pro-inflammatory cytokine release in mice with 
APOE knocked out followed by e4, e3, and e2 (Tai et al., 2015). The decreased pro-
inflammatory release in e4 mice compared to APOE knockout mice suggests that the 
ApoE4 protein carries a loss of function change rather than a gain of toxic function. Our 
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results support the hypothesis that presence of the APOE e4 allele results in a possible 
decrease in protective function of the immune system and associated with increased 
detrimental neuroinflammation that may be partially mediated by the ApoE protein. The 
ApoE e4 protein displays different interactions with DNA and proteins compared to e3 
and e2 that may underlie the observed immune response differences in e4 positive 
participants. The ApoE4 protein has been shown to directly bind promoter regions of 
genes associated with AD, altering their transcription (Theendakara et al., 2016). ApoE4 
is also more easily degraded resulting in lower ApoE levels in e4 carriers (Riddell et al., 
2008; Keene et al., 2011). While we did not observe a significant difference in ApoE 
protein levels between e4 positive and negative groups, ApoE4 has also been shown to 
decrease the amount of ApoE receptors in vitro which may in turn lead to altered 
responses to ApoE (Chen, Durakoglugil, Xian, & Herz, 2010). These are potential 
mechanisms underlying the differences between e4 positive and negative individuals. 
While the present study does not provide insight into which mechanism is involved it 
clearly shows a difference in the immune response between e4 positive and negative 
participants. The impact of ApoE protein levels appears to be different in the presence or 
absence of the e4 allele. ApoE protein levels may be involved in the negative association 
of cytokines and tau pathology in e4 negative individuals, however within e4 positive 
individuals it may contribute to the positive association of cytokines and microglia 
reflecting a heightened immune state.   
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LIMITATIONS  
Although the FHS brain donation cohort was recruited from the larger FHS 
community-based study, there is an autopsy-based selection bias. Tissue was generally 
collected locally as soon after death as possible, with the post-mortem interval less that 
14 hours in most cases. However, changes to tissue may have occurred between death 
and the time of collection that impacted our results. The associations between numerous 
cytokines and cell types and pathologies were studied. Cytokines were selected based on 
previous studies implicating them in human AD or mouse models of AD and multiple 
testing corrections were applied. Nevertheless, these limitations highlight the need for 
confirmation of our results in independent samples with a larger participant pool.  
 
CONCLUSION 
This study has revealed a clear difference in the immune system’s interaction with 
AD pathology between APOE e4 positive and negative individuals. Cytokines displayed 
a negative association with both amyloid and tau pathologies in e4 negative participants, 
indicating a potential protective role of the immune system in absence of e4. Specifically, 
increased IL-10, IL-13, IL-4, and IL-1a were associated with lower levels of tau 
pathology in the absence of e4. Total ApoE protein levels may partially mediate this 
effect. The negative association of cytokines and tau pathology is lost in e4 positive 
individuals, and instead we observed increased microglia density and increased tau 
pathology. Overall, APOE e4 appears to alter the associations of microglia and 
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inflammatory cytokines with AD pathologies. This potentially altered immune response 
and worse tau pathology within e4 carriers provide a possible mechanism explaining part 
of the increased risk for AD displayed by the APOE e4 allele. The results of this study 
may help guide future investigations into the role of neuroinflammation in AD and the 
modulatory impact of APOE and highlight the need to stratify by APOE genotype when 
studying immune interactions in AD.  
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